Author:
Sasaki Tomonari,Seto Takashi,Yamanaka Takeharu,Kunitake Naonobu,Shimizu Junichi,Kodaira Takeshi,Nishio Makoto,Kozuka Takuyo,Takahashi Toshiaki,Harada Hideyuki,Yoshimura Naruo,Tsutsumi Shinichi,Kitajima Hiromoto,Kataoka Masaaki,Ichinose Yukito,Nakagawa Kazuhiko,Nishimura Yasumasa,Yamamoto Nobuyuki,Nakanishi Yoichi
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
2. Segawa, Y. et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J. Clin. Oncol. 28, 3299–3306 (2010).
3. Yamamoto, N. et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J. Clin. Oncol. 28, 3739–3745 (2010).
4. Shirasaka, T. et al. Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56, 2602–2606 (1996).
5. Ichinose, Y. et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J. Thorac. Oncol. 6, 2069–2075 (2011).